ArticleDiscover oncology2025
Integrated transcriptomic and immunoinformatics analysis identifies tpx2, bub1b, and ube2c as diagnostic biomarkers and therapeutic targets in endometrial carcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectiveThis study aimed to identify novel diagnostic and prognostic biomarkers in endometrial carcinoma (EC) using integrative bioinformatics and immunohistochemical validation, with a focus on potential therapeutic targets and immune correlations.
methodsGene expression profiles from the GEO database (GSE63678 and GSE17025) and EC-related genes from the DisGeNET database were analyzed to identify overlapping differentially expressed genes (DEGs). Protein–protein interaction networks were constructed, and hub genes were identified using topological algorithms in Cytoscape. Functional enrichment was conducted via GO and KEGG analyses. Validation of hub gene expression was performed using GEPIA, Xiantao, and immunohistochemistry. Kaplan–Meier and ROC analyses assessed prognostic and diagnostic value. Immune infiltration correlations were analyzed using TIMER 2.0. Exploratory drug sensitivity analysis was performed using the GSCA platform.
resultsSixty-three EC-specific DEGs were identified. Ten hub genes were prioritized, with showing consistent overexpression in EC tissues across datasets and strong associations with poor survival. These genes were also linked to reduced immune cell infiltration and increased tumor purity. Preliminary analyses suggested positive correlations between tpx2/ube2c expression and trametinib/masitinib sensitivity.
conclusionbub1b, tpx2, and ube2c are promising biomarkers for the diagnosis and prognosis of EC. Their association with immunosuppression suggests a potential role in immune evasion. While pharmacogenomic are exploratory, they provide a basis for future investigation into their predictive value for targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.